Robert L. Lieff

Chemours Investors: Reminder About December 9, 2019 Filing Deadline in Class Action – Contact Lieff Cabraser

Retrieved on: 
Tuesday, November 5, 2019
Legal, Professional services, Lieff Cabraser Heimann & Bernstein, Law, Robert L. Lieff, Eric Gibbs

A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Key Points: 
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
  • You may retain Lieff Cabraser, or other attorneys, as your counsel in the actions.
  • Chemours investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.
  • The National Law Journal has recognized Lieff Cabraser as one of the nations top plaintiffs law firms for fourteen years.

MYGN Investors: Reminder About November 26, 2019 Filing Deadline in Class Action – Contact Lieff Cabraser

Retrieved on: 
Monday, October 28, 2019
Legal, Professional services, Lieff Cabraser Heimann & Bernstein, Robert L. Lieff

A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Key Points: 
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
  • Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff.
  • You may retain Lieff Cabraser, or other attorneys, as your counsel in the actions.
  • The National Law Journal has recognized Lieff Cabraser as one of the nations top plaintiffs law firms for fourteen years.

Myriad Genetics Investors: Filing Deadline in MYGN Class Action – Contact Lieff Cabraser

Retrieved on: 
Thursday, October 10, 2019
Legal, Professional services, Lieff Cabraser Heimann & Bernstein, Heimann, Robert L. Lieff, Myriad Genetics, Class action

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that securities fraud class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of Myriad Genetics, Inc. (Myriad or the Company) (NASDAQ: MYGN) between September 2, 2016 and August 13, 2019, inclusive (the Class Period).

Key Points: 
  • The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that securities fraud class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of Myriad Genetics, Inc. (Myriad or the Company) (NASDAQ: MYGN) between September 2, 2016 and August 13, 2019, inclusive (the Class Period).
  • You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.
  • Myriad investors may contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358 to learn more about the litigation and how to seek appointment as lead plaintiff .
  • The National Law Journal has recognized Lieff Cabraser as one of the nations top plaintiffs law firms for fourteen years.

PS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Pluralsight, Inc. (Nasdaq: PS)

Retrieved on: 
Monday, September 16, 2019
Legal, Professional services, Lieff Cabraser Heimann & Bernstein, Law, Robert L. Lieff

A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Key Points: 
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
  • You may retain Lieff Cabraser, or other attorneys, as your counsel in the actions.
  • The National Law Journal has recognized Lieff Cabraser as one of the nations top plaintiffs law firms for fourteen years.
  • For more information about Lieff Cabraser and the firms representation of investors, please visit http://www.lieffcabraser.com .

RBGLY INVESTORS NOTICE: Lieff Cabraser Reminds Investors of Deadline in Class Action Against Reckitt Benckiser Group plc

Retrieved on: 
Monday, August 12, 2019
Legal, Professional services, Lieff Cabraser Heimann & Bernstein, Law, Robert L. Lieff, Eric Gibbs

A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Key Points: 
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
  • You may retain Lieff Cabraser, or other attorneys, as your counsel in the actions.
  • RB Group investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.
  • The National Law Journal has recognized Lieff Cabraser as one of the nations top plaintiffs law firms for fourteen years.

OMCL INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Omnicell, Inc.

Retrieved on: 
Monday, August 5, 2019
Legal, Professional services, Lieff Cabraser Heimann & Bernstein, Heimann, Robert L. Lieff, Law, Law firm, Class action

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of Omnicell Inc. (Omnicell or the Company) (NASDAQ: OMCL) between October 25, 2018 and July 11, 2019, inclusive (the Class Period).

Key Points: 
  • The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of Omnicell Inc. (Omnicell or the Company) (NASDAQ: OMCL) between October 25, 2018 and July 11, 2019, inclusive (the Class Period).
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
  • The National Law Journal has recognized Lieff Cabraser as one of the nations top plaintiffs law firms for fourteen years.
  • For more information about Lieff Cabraser and the firms representation of investors, please visit http://www.lieffcabraser.com .

AOS INVESTORS NOTICE: Lieff Cabraser Reminds Investors of Deadline in Class Action Against A.O. Smith Corporation

Retrieved on: 
Monday, July 1, 2019
Legal, Professional services, Lieff Cabraser Heimann & Bernstein, Heimann, Law, Robert L. Lieff, Class action, Law firm, Eric Gibbs

The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action that has been filed on behalf of investors who purchased the common stock of A.O.

Key Points: 
  • The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action that has been filed on behalf of investors who purchased the common stock of A.O.
  • Smith Corporation (AOS or the Company) (NYSE: AOS) between July 26, 2016 through May 16, 2019, inclusive (the Class Period).
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
  • The National Law Journal has recognized Lieff Cabraser as one of the nations top plaintiffs law firms for fourteen years.

ADMS INVESTORS NOTICE: Lieff Cabraser Investigates Claims Against Adamas Pharmaceuticals, Inc.

Retrieved on: 
Monday, June 17, 2019
Professional services, Legal, Lieff Cabraser Heimann & Bernstein, Heimann, Law, Robert L. Lieff, Law firm

The law firm of Lieff Cabraser Heimann & Bernstein, LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (Adamas or the Company) (Nasdaq: ADMS), including investors who purchased Adamas common stock directly in the Companys January 24, 2018 secondary public offering (SPO).

Key Points: 
  • The law firm of Lieff Cabraser Heimann & Bernstein, LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (Adamas or the Company) (Nasdaq: ADMS), including investors who purchased Adamas common stock directly in the Companys January 24, 2018 secondary public offering (SPO).
  • Adamas investors who wish to learn more about the investigation should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.
  • The National Law Journal has recognized Lieff Cabraser as one of the nations top plaintiffs law firms for fourteen years.
  • For more information about Lieff Cabraser and the firms representation of investors, please visit http://www.lieffcabraser.com .

AOS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against A.O. Smith Corporation

Retrieved on: 
Tuesday, June 11, 2019
Professional services, Legal, Lieff Cabraser Heimann & Bernstein, Heimann, Eric Gibbs, Robert L. Lieff

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of A.O.

Key Points: 
  • The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of A.O.
  • Smith or the Company) (NYSE: AOS) between July 26, 2016 through May 16, 2019, inclusive (the Class Period).
  • Smith during the Class Period, you may move the Court for appointment as lead plaintiff by no later than July 29, 2019.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

ADMS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Adamas Pharmaceuticals, Inc.

Retrieved on: 
Monday, June 10, 2019
Professional services, Legal, Lieff Cabraser Heimann & Bernstein, Heimann, Law, Robert L. Lieff, Law firm

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of Adamas Pharmaceuticals, Inc. (Adamas or the Company) (Nasdaq: ADMS) directly in the Companys January 24, 2018 secondary public offering (SPO).

Key Points: 
  • The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of Adamas Pharmaceuticals, Inc. (Adamas or the Company) (Nasdaq: ADMS) directly in the Companys January 24, 2018 secondary public offering (SPO).
  • You may retain Lieff Cabraser, or other attorneys, as your counsel in the actions.
  • Adamas investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.
  • The National Law Journal has recognized Lieff Cabraser as one of the nations top plaintiffs law firms for fourteen years.